Mark Erlander - 09 Mar 2022 Form 4 Insider Report for Cardiff Oncology, Inc. (CRDF)

Role
Chief Executive Officer, Director
Signature
/s/ Mark Erlander
Issuer symbol
CRDF
Transactions as of
09 Mar 2022
Net transactions value
$0
Form type
4
Filing time
10 Mar 2022, 17:39:37 UTC
Previous filing
14 Jun 2021
Next filing
29 Nov 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRDF Stock Options Award $0 +370,128 +45% $0.000000 1,185,400 09 Mar 2022 Common Stock 370,128 $2.50 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 92,532 vest on 3/09/2023. 7,711 vest monthly for 36 months beginning on 4/09/2023 through 3/09/2026.